Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma Inc (ACST.VN)

Acasti Pharma Inc (ACST.VN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 27,130
  • Shares Outstanding, K 96,893
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 1.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.85
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings -0.05 on 06/30/20
  • Next Earnings Date 11/11/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

    TSX Bottom 100 Stocks

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.10
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.220 +27.27%
on 09/04/20
0.960 -70.83%
on 08/27/20
-0.610 (-68.54%)
since 08/25/20
3-Month
0.220 +27.27%
on 09/04/20
1.090 -74.31%
on 08/20/20
-0.530 (-65.43%)
since 06/25/20
52-Week
0.220 +27.27%
on 09/04/20
4.050 -93.09%
on 12/23/19
-2.430 (-89.67%)
since 09/25/19

Most Recent Stories

More News
Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST) announced that it has filed and mailed the information circular and management proxy statement (the "Circular") for its upcoming...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

FDA response expected on or before June 30, 2020

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

Patent upheld in Japan following opposition filings and subsequently allowed

ACST : 0.2190 (+2.53%)
ACST.VN : 0.280 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 0.293
1st Resistance Point 0.287
Last Price 0.280
1st Support Level 0.277
2nd Support Level 0.273

See More

52-Week High 4.050
Fibonacci 61.8% 2.587
Fibonacci 50% 2.135
Fibonacci 38.2% 1.683
Last Price 0.280
52-Week Low 0.220

See More

Business Summary

Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar